Topic
10 stories from Planck Standard. Latest: September 4, 2026.
Cleveland Clinic's first-in-human trial of the CRISPR therapy CTX310 dosed 15 patients and followed them for a year. The team reported no serious side effects tied to the treatment.
Phase 3 results showed young children with sickle cell disease or beta thalassemia became free of pain crises or transfusions after a single treatment that rewrites their own blood cells.
A Columbia-led team used base editing to correct disease-linked mutations in human embryos without the chromosomal damage seen in earlier CRISPR attempts — but warned of lingering off-target effects.
Researchers use advanced CRISPR technique to precisely edit embryo genes for the first time, raising both hope and ethical concerns.
Researchers identify NFIL3 as key factor causing engineered immune cells to lose cancer-fighting power, opening path to improved treatments.
Scientists behind Casgevy — the world's first CRISPR-based medicine — and Luxturna, the first gene replacement therapy to restore sight in children, were honored at the April 18 ceremony.
Researchers at Harvard and Beth Israel Deaconess Medical Center demonstrated for the first time that a modified CRISPR technique can silence the extra copy of chromosome 21 that causes Down syndrome in human stem cells, targeting the root cause rather than individual symptoms.
Stuart Orkin and Swee Lay Thein shared the $3 million prize for identifying the fetal hemoglobin switch that made the CRISPR therapy Casgevy possible — the first gene-editing treatment ever approved by the FDA.
The infant who received a custom-designed gene therapy built specifically for his unique genetic mutation marks his one-year anniversary walking, talking, and helping usher in a new FDA framework for individualized medicine.
Scientists at UNSW and St. Jude Children's Research Hospital demonstrated that removing methyl groups from silenced DNA can reactivate genes — potentially transforming treatment of sickle cell and other diseases.